{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:50:27Z","timestamp":1785451827752,"version":"3.56.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Edinburgh College of Medicine and Veterinary Medicine toward Wellcome","award":["108890\/B\/15\/Z"],"award-info":[{"award-number":["108890\/B\/15\/Z"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polypharmacy and use of anticholinergics are associated with adverse health outcomes. Because these 2 exposures covary, it is not known to what extent the detrimental health effects attributed to anticholinergic burden measured by anticholinergic burden scales (ABS) may be due to polypharmacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our aims were to evaluate the added effect beyond polypharmacy of (1) anticholinergic use and (2) scores according to existing ABS. We used linked data from the UK Biobank prospective cohort study to investigate drugs prescribed in primary care in the year 2015 (n = \u223c200 000; median age\u2009=\u200965 years). We randomly sampled among drugs to create 2000 pseudoscales\u2014drug burden scales designed to reflect the strength of the background effect of polypharmacy. We differentiated pseudoscales constructed to capture either general polypharmacy or putative anticholinergic polypharmacy. For each scale, we fitted logistic regression adjusted for confounders to assess associations between pseudoscales from each set and risk of death, dementia, or delirium. We also assessed 23 existing ABS by comparing them to the effects of pseudoscales that included the same numbers of drugs as each ABS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Odds ratios for death, dementia, and delirium using anticholinergic-polypharmacy pseudoscales (median\u2009=\u20091.09-1.10) were greater than those of general-polypharmacy pseudoscales (1.05-1.06). The added effect of anticholinergic use beyond polypharmacy was greater in adjusted models and when prescribed to participants when they were older. 35%-90% of ABS exhibited stronger effects than most pseudoscales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The models show an anticholinergic effect of drugs beyond polypharmacy or drug count, but it is small, ABS-dependent, and varies between outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/gerona\/glaf232","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:13:07Z","timestamp":1760703187000},"source":"Crossref","is-referenced-by-count":3,"title":["A simulation study comparing anticholinergic drug use with polypharmacy for risk of death, dementia, and delirium in UK Biobank"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0103-5139","authenticated-orcid":false,"given":"Jure","family":"Mur","sequence":"first","affiliation":[{"name":"Centre for Clinical Brain Sciences, University of Edinburgh , Edinburgh,","place":["United Kingdom"]},{"name":"Department of Social Sciences, Institute for Research on Socio-Economic Inequality (IRSEI), University of Luxembourg , Esch-sur-Alzette,","place":["Luxembourg"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy E","family":"Stirland","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, University of Edinburgh , Edinburgh,","place":["United Kingdom"]},{"name":"Global Brain Health Institute, University of California San Francisco , San Francisco, California,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Muniz-Terrera","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, University of Edinburgh , Edinburgh,","place":["United Kingdom"]},{"name":"Heritage College of Osteopathic Medicine, Ohio University , Athens, Ohio,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5074-5209","authenticated-orcid":false,"given":"Anja K","family":"Leist","sequence":"additional","affiliation":[{"name":"Department of Social Sciences, Institute for Research on Socio-Economic Inequality (IRSEI), University of Luxembourg , Esch-sur-Alzette,","place":["Luxembourg"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"2025112418471512900_glaf232-B1","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3389\/fphar.2020.00570","article-title":"The prognostic value of anticholinergic burden measures in relation to mortality in older individuals: a systematic review and meta-analysis","volume":"11","author":"Graves-Morris","year":"2020","journal-title":"Front Pharmacol"},{"key":"2025112418471512900_glaf232-B2","first-page":"CD015196","article-title":"Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia","volume":"8","author":"Taylor-Rowan","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2025112418471512900_glaf232-B3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/acps.13505","article-title":"Delirium-associated medication in people at risk. A systematic update review, meta-analyses and GRADE-profiles","volume":"147","author":"Reisinger","year":"2022","journal-title":"Acta Psychiatr Scand"},{"key":"2025112418471512900_glaf232-B4","doi-asserted-by":"crossref","first-page":"20420986211016645","DOI":"10.1177\/20420986211016645","article-title":"Anticholinergic burden measures and older people\u2019s falls risk: a systematic prognostic review","volume":"12","author":"Stewart","year":"2021","journal-title":"Ther Adv Drug Saf"},{"key":"2025112418471512900_glaf232-B5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40780-021-00213-y","article-title":"A meta-analysis of observational studies on anticholinergic burden and fracture risk: evaluation of conventional burden scales","volume":"7","author":"Ogawa","year":"2021","journal-title":"J Pharm Health Care Sci"},{"key":"2025112418471512900_glaf232-B6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s40266-018-0549-z","article-title":"anticholinergic drug burden tools\/scales and adverse outcomes in different clinical settings: a systematic review of reviews","volume":"35","author":"Welsh","year":"2018","journal-title":"Drugs Aging"},{"key":"2025112418471512900_glaf232-B7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jamda.2019.10.022","article-title":"Adverse outcomes of polypharmacy in older people: systematic review of reviews","volume":"21","author":"Davies","year":"2020","journal-title":"J Am Med Dir Assoc"},{"key":"2025112418471512900_glaf232-B8","doi-asserted-by":"crossref","first-page":"2042098620933741","DOI":"10.1177\/2042098620933741","article-title":"An overview of prevalence, determinants and health outcomes of polypharmacy","volume":"11","author":"Khezrian","year":"2020","journal-title":"Ther Adv Drug Saf"},{"key":"2025112418471512900_glaf232-B9","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1080\/13607863.2018.1468411","article-title":"Association between polypharmacy and dementia\u2014a systematic review and metaanalysis","volume":"23","author":"Leelakanok","year":"2019","journal-title":"Aging Ment Health"},{"key":"2025112418471512900_glaf232-B10","doi-asserted-by":"crossref","first-page":"902599","DOI":"10.3389\/fpubh.2022.902599","article-title":"The risk of falls among the aging population: a systematic review and meta-analysis","volume":"10","author":"Xu","year":"2022","journal-title":"Front Public Health"},{"key":"2025112418471512900_glaf232-B11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12916-015-0322-7","article-title":"The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010","volume":"13","author":"Guthrie","year":"2015","journal-title":"BMC Med"},{"key":"2025112418471512900_glaf232-B12","doi-asserted-by":"crossref","first-page":"20420986241259624","DOI":"10.1177\/20420986241259624","article-title":"Anticholinergic burden among in-patients: a cross-sectional study on prevalence, determinants, and impact on mortality in Ethiopia","volume":"15","author":"Gebreyohannes","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"2025112418471512900_glaf232-B13","doi-asserted-by":"crossref","first-page":"e0253336","DOI":"10.1371\/journal.pone.0253336","article-title":"Anticholinergic burden: first comprehensive analysis using claims data shows large variation by age and sex","volume":"16","author":"Reinold","year":"2021","journal-title":"PLoS One"},{"key":"2025112418471512900_glaf232-B14","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/bcp.15045","article-title":"Increase in anticholinergic burden from 1990 to 2015: age-period-cohort analysis in UK biobank","volume":"88","author":"Mur","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2025112418471512900_glaf232-B15","first-page":"e12290","article-title":"Association between anticholinergic burden and dementia in UK Biobank","volume":"8","author":"Mur","year":"2022","journal-title":"Alzheimers Dement"},{"key":"2025112418471512900_glaf232-B16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jacc.2021.03.342","article-title":"United Kingdom Biobank (UK Biobank): JACC Focus Seminar 6\/8","volume":"78","author":"Caleyachetty","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025112418471512900_glaf232-B17","doi-asserted-by":"crossref","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"key":"2025112418471512900_glaf232-B18","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/bcp.15698","article-title":"Anticholinergic burden in middle and older age is associated with lower cognitive function, but not with brain atrophy","volume":"89","author":"Mur","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"2025112418471512900_glaf232-B19","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/jamia\/ocab260","article-title":"Curating a longitudinal research resource using linked primary care EHR data-a UK Biobank case study","volume":"29","author":"Darke","year":"2022","journal-title":"J Am Med Inform Assoc"},{"key":"2025112418471512900_glaf232-B20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"\u00adLancet"},{"key":"2025112418471512900_glaf232-B21","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(13)60688-1","article-title":"Delirium in elderly \u00adpeople","volume":"383","author":"Inouye","year":"2014","journal-title":"Lancet"},{"key":"2025112418471512900_glaf232-B22","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/gps.4823","article-title":"Delirium pathophysiology: an updated hypothesis of the etiology of acute brain failure","volume":"33","author":"Maldonado","year":"2018","journal-title":"Int J Geriatr Psychiatry"},{"key":"2025112418471512900_glaf232-B23","author":"Office for National Statistics (ONS)","year":"2020"},{"key":"2025112418471512900_glaf232-B24","author":"UK Biobank","year":"2022"},{"key":"2025112418471512900_glaf232-B25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10654-019-00499-1","article-title":"Identifying dementia outcomes in UK Biobank: a validation study of primary care, hospital admissions and mortality data","volume":"34","author":"Wilkinson","year":"2019","journal-title":"Eur J Epidemiol"},{"key":"2025112418471512900_glaf232-B26","author":"UK Biobank","year":"2019"},{"key":"2025112418471512900_glaf232-B27","doi-asserted-by":"crossref","first-page":"e1387","DOI":"10.1212\/WNL.0000000000007136","article-title":"Vitamin D levels and risk of delirium: a Mendelian randomization study in the UK Biobank","volume":"92","author":"Bowman","year":"2019","journal-title":"Neurology"},{"key":"2025112418471512900_glaf232-B28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/jgs.16853","article-title":"Low vitamin D levels and risk of incident delirium in 351,000 older UK Biobank participants","volume":"69","author":"Pilling","year":"2021","journal-title":"J Am Geriatr Soc"},{"key":"2025112418471512900_glaf232-B29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/gerona\/glab272","article-title":"Association of poor sleep burden in middle age and older adults with risk for delirium during hospitalization","volume":"77","author":"Ulsa","year":"2022","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2025112418471512900_glaf232-B30","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1111\/j.1532-5415.2008.02009.x","article-title":"Cumulative anticholinergic exposure is associated with poor memory and executive function in older men","volume":"56","author":"Han","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"2025112418471512900_glaf232-B31","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/archinternmed.2007.106","article-title":"The anticholinergic risk scale and anticholinergic adverse effects in older persons","volume":"168","author":"Rudolph","year":"2008","journal-title":"Arch Intern Med."},{"key":"2025112418471512900_glaf232-B32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000325171","article-title":"Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study","volume":"31","author":"Sittironnarit","year":"2011","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2025112418471512900_glaf232-B33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1613\/jair.953","article-title":"SMOTE: synthetic minority over-sampling technique","volume":"16","author":"Chawla","year":"2002","journal-title":"JAIR"},{"key":"2025112418471512900_glaf232-B34","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.2517-6161.1991.tb01857.x","article-title":"A reliable data-based bandwidth selection method for kernel density estimation","volume":"53","author":"Sheather","year":"1991","journal-title":"Journal of the Royal Statistical Society: Series B (Methodological)"},{"key":"2025112418471512900_glaf232-B35","doi-asserted-by":"crossref","first-page":"e0151084","DOI":"10.1371\/journal.pone.0151084","article-title":"Serum anticholinergic activity and cognitive and functional adverse outcomes in older people: a systematic review and meta-analysis of the literature","volume":"11","author":"Salahudeen","year":"2016","journal-title":"PLoS One"},{"key":"2025112418471512900_glaf232-B36","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"2025112418471512900_glaf232-B37","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/pds.5407","article-title":"Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators","volume":"31","author":"Sendor","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025112418471512900_glaf232-B38","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/aje\/kwx246","article-title":"Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population","volume":"186","author":"Fry","year":"2017","journal-title":"Am J Epidemiol"},{"key":"2025112418471512900_glaf232-B39","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00228-015-1932-x","article-title":"Different methods, different results\u2014how do available methods link a patient\u2019s anticholinergic load with adverse outcomes?","volume":"71","author":"Mayer","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"2025112418471512900_glaf232-B40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.56.2.4","article-title":"Aging biology and geriatric clinical pharmacology","volume":"56","author":"McLean","year":"2004","journal-title":"Pharmacol Rev"},{"key":"2025112418471512900_glaf232-B41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/1745509X.4.3.311","article-title":"Impact of anticholinergics on the aging brain: a review and practical application","volume":"4","author":"Boustani","year":"2008","journal-title":"Aging Health"},{"key":"2025112418471512900_glaf232-B42","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1177\/0091270006292126","article-title":"The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity","volume":"46","author":"Carnahan","year":"2006","journal-title":"J Clin Pharmacol"}],"container-title":["The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/biomedgerontology\/advance-article-pdf\/doi\/10.1093\/gerona\/glaf232\/64881508\/glaf232.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biomedgerontology\/article-pdf\/80\/12\/glaf232\/64881508\/glaf232.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biomedgerontology\/article-pdf\/80\/12\/glaf232\/64881508\/glaf232.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T23:47:24Z","timestamp":1764028044000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/biomedgerontology\/article\/doi\/10.1093\/gerona\/glaf232\/8300166"}},"subtitle":[],"editor":[{"given":"Lewis A","family":"Lipsitz","sequence":"additional","affiliation":[{"name":"(Medical Sciences Section)"}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11,6]]}},"URL":"https:\/\/doi.org\/10.1093\/gerona\/glaf232","relation":{},"ISSN":["1079-5006","1758-535X"],"issn-type":[{"value":"1079-5006","type":"print"},{"value":"1758-535X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,23]]},"article-number":"glaf232"}}